Literature DB >> 17475837

CD8+ T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-alpha-dependent mechanism.

Dru S Dace1, Peter W Chen, Jerry Y Niederkorn.   

Abstract

Although intraocular tumors reside in an immune-privileged environment, T cells can circumvent immune privilege and mediate tumor rejection without inducing damage to normal ocular tissue. In this study, we used a well-characterized tumor, Ad5E1 (adenovirus type 5 early region 1), to analyze the role of CD8+ T cells in the pristine rejection of intraocular tumors. It has been previously documented that Ad5E1 tumor rejection can occur in the absence of CD8+ T cells. However, here we find that CD8+ T cells infiltrated intraocular Ad5E1 tumors in C57BL/6 mice. Surprisingly, CD8+ T cells from tumor-rejector mice could mediate intraocular tumor rejection following adoptive transfer to SCID mice. In determining the mechanisms behind CD8+ T cell-mediated tumor rejection, we discovered that antitumor CTL activity was neither observed nor necessary for rejection of the intraocular tumors. CD8+ T cells from rejector mice did not produce IFN-gamma in response to Ad5E1 tumor Ags or use FasL to mediate intraocular tumor rejection. Also, CD8+ T cells did not use perforin or TRAIL, as CD8+ T cells from perforin knockout (KO) and TRAIL KO mice conferred protection to SCID recipient mice following adoptive transfer. We discovered that CD8+ T cells used TNF-alpha to mediate tumor rejection, because Ad5E1 tumor cells were highly sensitive to TNF-alpha-induced apoptosis and CD8+ T cells from TNF-alpha KO mice did not protect SCID mice from progressive Ad5E1 tumor growth. The results indicate that CD8+ T cells circumvent immune privilege and mediate intraocular tumor rejection by a TNF-alpha-dependent manner while leaving the eye intact and vision preserved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475837     DOI: 10.4049/jimmunol.178.10.6115

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

Review 2.  Influence of immune privilege on ocular tumor development.

Authors:  Kyle C McKenna; Peter W Chen
Journal:  Ocul Immunol Inflamm       Date:  2010-04       Impact factor: 3.070

3.  Abrogating TNF-α expression prevents bystander destruction of normal tissues during iNOS-mediated elimination of intraocular tumors.

Authors:  Terry G Coursey; Peter W Chen; Jerry Y Niederkorn
Journal:  Cancer Res       Date:  2011-02-09       Impact factor: 12.701

4.  IFN-γ-independent intraocular tumor rejection is mediated by a macrophage-dependent process that leaves the eye intact.

Authors:  Terry G Coursey; Peter W Chen; Jerry Y Niederkorn
Journal:  J Leukoc Biol       Date:  2012-06-12       Impact factor: 4.962

5.  Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activation.

Authors:  Antonio Sorrentino; Ayse Nur Menevse; Tillmann Michels; Valentina Volpin; Franziska Christine Durst; Julian Sax; Maria Xydia; Abir Hussein; Slava Stamova; Steffen Spoerl; Nicole Heuschneider; Jasmin Muehlbauer; Katharina Marlene Jeltsch; Anchana Rathinasamy; Melanie Werner-Klein; Marco Breinig; Damian Mikietyn; Christian Kohler; Isabel Poschke; Sabrina Purr; Olivia Reidell; Catarina Martins Freire; Rienk Offringa; Claudia Gebhard; Rainer Spang; Michael Rehli; Michael Boutros; Christian Schmidl; Nisit Khandelwal; Philipp Beckhove
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

Review 6.  Tumor necrosis factor and cancer, buddies or foes?

Authors:  Xia Wang; Yong Lin
Journal:  Acta Pharmacol Sin       Date:  2008-11       Impact factor: 6.150

Review 7.  Intravital imaging of CD8+ T cell function in cancer.

Authors:  Thorsten R Mempel; Christian A Bauer
Journal:  Clin Exp Metastasis       Date:  2008-07-30       Impact factor: 5.150

8.  CD4+ T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages.

Authors:  Dru S Dace; Peter W Chen; Jerry Y Niederkorn
Journal:  Immunology       Date:  2007-10-17       Impact factor: 7.397

9.  Adoptive immunotherapy with Cl-IB-MECA-treated CD8+ T cells reduces melanoma growth in mice.

Authors:  Antonella Montinaro; Giovanni Forte; Rosalinda Sorrentino; Antonio Luciano; Giuseppe Palma; Claudio Arra; Ian M Adcock; Aldo Pinto; Silvana Morello
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

10.  Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy.

Authors:  N Kanagawa; T Yanagawa; T Nakagawa; N Okada; S Nakagawa
Journal:  Cancer Gene Ther       Date:  2012-11-23       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.